Supplementary Figure 1:
Functional expression of recombinant NR1/NR3 receptors after transient cotransfection in mammalian HEK293 cells. HEK293 cells were transfected with the following subunit combinations: NR1 (NR1 or NR1-GFP) plus NR3A (NR3A or NR3A-YFP), or NR1 (NR1 or NR1-GFP) plus NR3B. When expression was assayed 24 to 72 hours post-transfection, we detected functional receptors activated by glycine in about 10% of all GFP-positive cells. A-C, Whole-cell responses recorded at different membrane potentials from HEK293 cells transduced with A, NR1/NR3A (1:2 ratio), B, NR1/NR3B (1:2 ratio), or C, NR1/NR3A/NR3B subunits (1:2:2 ratio). Whole-cell currents in response to a 300 ms application of glycine. D, Mean current density of wholecell responses to glycine (n = 8 for each condition). E, Current-voltage (I/V) relationship for cells transfected with NR1/NR3A-YFP/NR3B. Recordings were performed during application of glycine at holding potentials between -80 and +30 mV. Mean current-density values were very small in response to application of glycine concentrations of 10 µM up to 1 mM for NR1/NR3A (0.3 pA/pF) and NR1/NR3B (1.5 ± 0.5 pA/pF) receptors (n = 5 each). NR1/NR3A/NR3B receptors yielded a larger mean current density of 41 ± 12 pA/pF (n = 10). Glycine-evoked currents were excitatory in nature since they reversed at ~0 mV in the presence of symmetrical cation and asymmetrical anion solutions on either side of the membrane (inset at right; n = 6). A, We analyzed the kinetics of NR1/NR3 receptors by comparing the decay of NMDA and/or glycine-evoked whole-cell currents in HEK293 cells transfected with NR1/NR3A/NR3B subunits versus classical NR1/NR2A NMDARs. Use of a fast application system revealed currents with a large rapidly desensitizing component (91 ± 1.8% of peak amplitude; n=15) and a smaller but persistent non-desensitizing component (9 ± 1.8% of peak amplitude; n=15) for NR1/NR3 receptors. The desensitizing component in NR1/NR3 receptormediated responses had mean decay time constants of about 100 ms compared to 800 ms for NR1/NR2A receptors (Supplementary Table 1) . B, Recovery of glycine-evoked current from desensitization. Complete recovery (re-sensitization) was achieved 7.5 s after the end of the conditioning pulse (τ 1/2 = 2.27 ± 0.41 s). To analyze recovery from desensitization, we applied test applications of 200 µM glycine at increments of 2.5 seconds to cells expressing NR1/NR3A/NR3B receptors. We observed ~ 93% recovery of the control response within 5 seconds of the first application of agonist and complete recovery within 7.5 s of the first agonist application. Recovery from desensitization occurred with a time constant τ = 2.27 ± 0.41 s (n = 6). No currents were observed when glycine was applied to non-transfected cells (n = 11) or to cells transfected with a single subunit (NR1, NR3A or NR3B; n = 17; data not shown). Holding potential, -60 mV. mV, although some degree of blockade developed at more negative potentials. C, 519 [(E)-3-(2-phenyl-2-carboxyethenyl)-4, 6-dichloro-1H-indole-2-carboxylic acid], an antagonist of the NR1 glycine binding-site (Baron et al. 1996) , exhibited a long-lasting, dual-effect on glycine-evoked currents, inhibiting peak current but potentiating steady-state current. The glycine-binding site antagonist 5,7-dichlorokynurenic acid (5,7-dichloro-4-hydroxyquinoline-2-carboxylic acid; DCKA; Baron et al. 1991) had similar dual effects on glycine-evoked currents (data not shown). Effects were concentration-dependent and reversible. Complete recovery of peak and steady-state responses from antagonist usually occurred within 3 min. Holding potential, -60 mV. Table 1 Decay time constants of glycine or glycine/glutamate evoked currents. 
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